TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06274983

Intervention type: DEVICE
Group type: OTHER
Intervention: IVR platform trial
Description: 8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform. Patients will receive device training and then use the VR device at home for 12 weeks. Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
Study: NCT05409248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham cognitive stimulation
Description: Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
Study: NCT05859399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
Study: NCT03886025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Iowa Gambling Task will be used for cognitive training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Iowa Gambling Task will be used for cognitive training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive brain stimulation
Study: NCT06342323

Intervention type: RADIATION
Intervention: SBRT
Description: the fiducial marker was implanted with 3D template assistance under CT guidance
Study: NCT05997017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
Study: NCT04565418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
Study: NCT06502275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Management Frailty Care Program
Description: Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise.
Study: NCT05583110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule.
Study: NCT05369078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-1442 20mg Single dose
Description: THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-1442 20mg Multiple dose group
Description: THR-1442 20mg is administrated QD for 7days, then follow till day 14.
Study: NCT05101226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga attended in person
Description: One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
Study: NCT05467319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose Injection
Description: 1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100 mL of 0.9% normal saline (w/v) by intravenous infusion
Study: NCT05101226

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga attended in person
Description: One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga attended online
Description: One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga attended online
Description: One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
Study: NCT04700280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970
Description: GLPG3970 film-coated tablet.
Study: NCT05992129

Intervention type: OTHER
Group type: OTHER
Intervention: foot exercise
Description: These are foot and ankle muscle strengthening exercises described and evaluated by the literature

Intervention type: OTHER
Group type: OTHER
Intervention: foot exercise
Description: These are foot and ankle muscle strengthening exercises described and evaluated by the literature
Study: NCT04700280

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablet.
Study: NCT06345755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-407
Description: Solution or Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-407
Description: Solution or Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-407
Description: Solution or Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution or Suspension for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution or Suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration.
Study: NCT06335823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcutaneous electrical nerve stimulation (TENS)
Description: All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
Study: NCT06364644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Champions
Description: The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
Study: NCT05875922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental (ISOPURE 1.2.3.)
Description: Implantation of premium monofocal IOL ISOPURE 1.2.3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator (TECNIS Eyhance)
Description: Implantation of EDOF IOL TECNIS Eyhance
Study: NCT06364644

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homegrown Heroes
Description: Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
Study: NCT05807178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Light Therapy Device, LSA-1
Description: Dynamic Light Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Light Therapy Device, LSA-2
Description: Dynamic Light Therapy
Study: NCT05414292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune (sirolimus) 1Mg Tablet
Description: Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral resistance exercise training
Description: Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unilateral resistance exercise training
Description: Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
Study: NCT06108349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
Study: NCT05075083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: receive two doses inactivated COVID-19 vaccine with the interval of 21 days
Study: NCT05890885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real left prefrontal tDCS - sham
Description: Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
Study: NCT04750044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early refeeding
Description: In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
Study: NCT05890885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham - Real left prefrontal tDCS
Description: Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
Study: NCT04750044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed refeeding
Description: In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.
Study: NCT06153810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback stimulation
Description: Delivery of the vibratory biofeedback stimulus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback stimulation
Description: Delivery of the vibratory biofeedback stimulus
Study: NCT06117332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual prosthesis
Description: In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information.
Study: NCT06061575

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: fever will be managed with acetaminophen

Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: fever will be managed with ibuprofen
Study: NCT05903937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: Administered via hepatic arterial infusion (HAI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered via isolated hepatic perfusion
Study: NCT05522738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination: Fruquintinib + FOLFIRI
Description: Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w
Study: NCT06589050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toe flexor device experimental group
Description: This intervention group will perform toe flexion using a toe flexor (TF) device, which facilitates the shortening and stretching of the TF muscle-tendon units (MTUs) against resistance bands. While seated, participants will push a pedal down with their toes over two counts and release it over two counts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined Heel Rise experimental group
Description: This intervention group will perform single-leg heel rises on an inclined platform. Participants will place their hands against a barre for balance support, lift their heels over two counts, and lower them over two counts.
Study: NCT06326021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous FL-33 CAR T therapy
Description: Autologous FL-33 CAR T cells are infused intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prior-HSCT donor-derived FL-33 CAR T therapy
Description: Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
Study: NCT06073678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Irradiation with red laser on palate wound each 48h for 4 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protection with surgical dressing
Description: Protection of the palatal wound with surgical dressing for 7 days
Study: NCT06607991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab Treatment
Description: Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Study: NCT06681649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge
Study: NCT06072183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: 100mg Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: 100mg Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: 50mg Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule
Study: NCT05233397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
Study: NCT06689553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Continual Fluid Removal System
Description: The intraperitoneal device is percutaneously implanted via mini laparotomy, under local anaesthesia and sedation, and connected to the wearable rechargeable pump through extracorporeal tubing. The device aims to remove excess fluids in heart failure patients with diuretic resistance
Study: NCT06623019

Intervention type: DIAGNOSTIC_TEST
Intervention: Validation and reliability
Description: As this is a cross-sectional validation study, there is no intervention.
Study: NCT06629688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
Study: NCT04989387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA00186
Description: INCA00186 will be administered every 2 weeks or 4 weeks as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA00186
Description: INCA00186 will be administered every 2 weeks or 4 weeks as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA00186
Description: INCA00186 will be administered every 2 weeks or 4 weeks as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA00186
Description: INCA00186 will be administered every 2 weeks or 4 weeks as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered every 4 weeks as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered every 4 weeks as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB106385
Description: INCB106385 will be administered orally once or twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB106385
Description: INCB106385 will be administered orally once or twice a day.
Study: NCT05766969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD/PEA
Description: A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive compound.
Study: NCT05903937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low-dose, administered s.c.
Study: NCT05758597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remazolam besylate
Description: Remazolam benzoate group was given 0.1-1mg/kg/h, and the target RASS score was maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Meanwhile the midazolam group was given 0.05-0.2 mg/kg/h midazolam, and the target RASS score was maintained.